Tenaya Therapeutics could earn up to $1.1B for new heart disease research

2026-04-03 15:51:22

Abstract generation in progress

Tenaya Therapeutics and Alnylam Pharmaceuticals have partnered to identify new treatments for cardiovascular disease. Tenaya Therapeutics will validate up to 15 gene targets for Alnylam, receiving an initial $10 million payment and potentially up to $1.13 billion in total. This collaboration leverages Tenaya’s expertise in gene target identification and Alnylam’s leadership in RNA interference to develop innovative medicines for heart conditions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes